Monoclonal Antibodies Offer Potential Option in Rabies Treatment
Human monoclonal antibodies (mAbs) targeting the rabies glycoprotein are being investigated as a promising alternative to rabies immunoglobulin (RIG) for post-exposure prophylaxis. this approach aims to neutralize the rabies virus at the wound site, providing crucial protection until the body develops its own neutralizing antibodies through vaccination. RIG has historically been the standard for immediate antibody protection, but monoclonal antibodies offer potential advantages in terms of production, consistency, and availability.
Recent research, particularly studies conducted in India, has demonstrated the effectiveness of rabies monoclonal antibodies (RmAb) developed by the Serum Institute of India. These studies reveal that the critical amino acid residues on the rabies glycoprotein responsible for neutralization by the RmAb are consistently present – or conserved – across all rabies virus isolates found in terrestrial animals. this conservation is a significant finding, suggesting broad efficacy of these mAbs against diverse rabies strains.
The growth of broadly neutralizing monoclonal antibodies is crucial because rabies viruses exhibit genetic diversity. The conserved nature of the neutralization epitopes identified in the Serum institute of india’s RmAb indicates a potential for a universally effective antibody treatment. This could simplify rabies post-exposure prophylaxis, particularly in resource-limited settings where access to RIG might potentially be challenging.
Currently, rabies post-exposure prophylaxis typically involves wound cleansing, administration of RIG, and a series of rabies vaccinations. Monoclonal antibodies, if proven equally or more effective, could potentially streamline this process, reducing costs and improving accessibility to life-saving treatment. Further research and clinical trials are ongoing to fully evaluate the safety and efficacy of these monoclonal antibody therapies.
Sources:
Related reading